In the Journals

Dexamethasone implant for macular edema improves VA, CRT

Patients with macular edema who received a dexamethasone intravitreal implant experienced significantly improved best corrected visual acuity and central retinal thickness over a 1-year period, according to study.

The prospective, open-label, multicenter study included 71 patients with macular edema for less than 3 months. The primary endpoint was mean change from baseline in best corrected visual acuity (BCVA) at 6 months, and secondary was increase in BCVA of 15 letters or more at months 6 and 12.

Only 59 patients completed the 12-month study and 62 patients remained at the 6-month timepoint. Retreatment was allowed for patients at 4 months or less.

At 6 months, the mean BCVA improved by 18.6 letters; at 1 year, the mean BCVA improved by 15.3 letters. At 6 months, the mean decrease in central retinal thickness (CRT) from baseline was 246.8 m. At 1 year, the mean decrease in CRT was 196.9 m.

Across the 12-month study period, 32% of patients had one dexamethasone intravitreal implant injection, 18% had two injections, and 49% had three injections. The mean CRT of patients who received one injection was significantly thinner than in those who received three injections (P < .016). – by Robert Linnehan

Disclosures: Yoon reports receiving a research grant, consulting fees and speaker fees from Allergan plc. Please see the full study for a list of all other authors’ relevant financial disclosures.

Patients with macular edema who received a dexamethasone intravitreal implant experienced significantly improved best corrected visual acuity and central retinal thickness over a 1-year period, according to study.

The prospective, open-label, multicenter study included 71 patients with macular edema for less than 3 months. The primary endpoint was mean change from baseline in best corrected visual acuity (BCVA) at 6 months, and secondary was increase in BCVA of 15 letters or more at months 6 and 12.

Only 59 patients completed the 12-month study and 62 patients remained at the 6-month timepoint. Retreatment was allowed for patients at 4 months or less.

At 6 months, the mean BCVA improved by 18.6 letters; at 1 year, the mean BCVA improved by 15.3 letters. At 6 months, the mean decrease in central retinal thickness (CRT) from baseline was 246.8 m. At 1 year, the mean decrease in CRT was 196.9 m.

Across the 12-month study period, 32% of patients had one dexamethasone intravitreal implant injection, 18% had two injections, and 49% had three injections. The mean CRT of patients who received one injection was significantly thinner than in those who received three injections (P < .016). – by Robert Linnehan

Disclosures: Yoon reports receiving a research grant, consulting fees and speaker fees from Allergan plc. Please see the full study for a list of all other authors’ relevant financial disclosures.